Abstract

Introduction/BackgroundPatients with advanced epithelial ovarian cancer (EOC) have a poor prognosis. The Olaparib significantly prolonged their progression-free survival (PFS). However, its tolerability in Asian population and the role of low...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call